Trichinellosis

Summary

Trichinellosis (MONDO:0019444) is a disease and 1 clinical trial. Top therapeutic interventions include silodosin. A subtype of Enoplea infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]
• Phenotypes (HPO): 42
• Clinical trials: 1

Clinical features

Epidemiology

Prevalence records

9 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	<1 / 1 000 000	0.06	Europe	Validated
Annual incidence	1-9 / 1 000 000	0.48	Bulgaria	Validated
Annual incidence	<1 / 1 000 000	0.067	Croatia	Validated
Annual incidence	<1 / 1 000 000	0.04	Estonia	Validated
Annual incidence	<1 / 1 000 000	0.04	Italy	Validated
Annual incidence	1-9 / 100 000	1.06	Latvia	Validated
Annual incidence	1-9 / 1 000 000	0.6	Lithuania	Validated
Annual incidence	1-9 / 1 000 000	0.64	Romania	Validated
Annual incidence	<1 / 1 000 000	0.08	Slovakia	Validated

Signs & symptoms

Clinical features (HPO)

42 HPO clinical features (Orphanet curated; top 42 by frequency):

HPO ID	Term	Frequency
HP:0000282	Facial edema	Frequent (30-79%)
HP:0000969	Edema	Frequent (30-79%)
HP:0001265	Hyporeflexia	Frequent (30-79%)
HP:0001324	Muscle weakness	Frequent (30-79%)
HP:0002018	Nausea	Frequent (30-79%)
HP:0003212	Increased circulating IgE level	Frequent (30-79%)
HP:0003457	EMG abnormality	Frequent (30-79%)
HP:0030953	Conjunctival hyperemia	Frequent (30-79%)
HP:0100539	Periorbital edema	Frequent (30-79%)
HP:0000211	Trismus	Occasional (5-29%)
HP:0000360	Tinnitus	Occasional (5-29%)
HP:0000496	Abnormality of eye movement	Occasional (5-29%)
HP:0000509	Conjunctivitis	Occasional (5-29%)
HP:0000602	Ophthalmoplegia	Occasional (5-29%)
HP:0000708	Atypical behavior	Occasional (5-29%)
HP:0000737	Irritability	Occasional (5-29%)
HP:0000741	Apathy	Occasional (5-29%)
HP:0000988	Skin rash	Occasional (5-29%)
HP:0001254	Lethargy	Occasional (5-29%)
HP:0001262	Excessive daytime somnolence	Occasional (5-29%)
HP:0001269	Hemiparesis	Occasional (5-29%)
HP:0001289	Confusion	Occasional (5-29%)
HP:0001626	Abnormality of the cardiovascular system	Occasional (5-29%)
HP:0002015	Dysphagia	Occasional (5-29%)
HP:0002321	Vertigo	Occasional (5-29%)
HP:0002354	Memory impairment	Occasional (5-29%)
HP:0002921	Abnormality of the cerebrospinal fluid	Occasional (5-29%)
HP:0004372	Reduced consciousness/confusion	Occasional (5-29%)
HP:0005986	Limitation of neck motion	Occasional (5-29%)
HP:0200026	Ocular pain	Occasional (5-29%)
HP:0000553	Abnormal uvea morphology	Very rare (<1-4%)
HP:0000573	Retinal hemorrhage	Very rare (<1-4%)
HP:0000587	Abnormal optic nerve morphology	Very rare (<1-4%)
HP:0000651	Diplopia	Very rare (<1-4%)
HP:0001287	Meningitis	Very rare (<1-4%)
HP:0001298	Encephalopathy	Very rare (<1-4%)
HP:0002301	Hemiplegia	Very rare (<1-4%)
HP:0002381	Aphasia	Very rare (<1-4%)
HP:0003487	Babinski sign	Very rare (<1-4%)
HP:0009916	Anisocoria	Very rare (<1-4%)
HP:0010628	Facial palsy	Very rare (<1-4%)
HP:0025342	Central retinal artery occlusion	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	trichinellosis
Mondo ID	MONDO:0019444
MeSH	D014235
Orphanet	863
DOID	DOID:9784
ICD-10-CM	B75
ICD-11	284613639
NCIT	C85199
SNOMED CT	709018004
UMLS	C0040896
MedGen	21645
GARD	0005250
MedDRA	10044608
Is cancer (heuristic)	no

Also known as: Human trichinellosis · infection with Trichinella · Trichinella caused disease or disorder · Trichinella disease or disorder · Trichinella infectious disease · Trichinella spiralis infection · trichiniasis · trichinosis

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › helminthiasis › Nematoda infectious disease › Enoplea infectious disease › trichinellosis

Related subtypes (3): dioctophymiasis, capillariasis, trichuriasis

Subtypes (1): Trichinella spiralis infectious disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

3 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Dexamethasone	Approved (phase 4)
Prednisolone	Approved (phase 4)
Prednisone	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06332235	Not specified	UNKNOWN	Efficacy and Safety of Silodosin in the Treatment of Lower Urinary Tract Symptoms in Taiwanese Population.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SILODOSIN	4	1